This is a major derisking event for PHVS. The 83% attack rate reduction with statistical significance across all HAE types, combined with a clean safety profile, positions deucrictibant XR as a potential best-in-class oral prophylactic. Traders should watch for the NDA submission timeline (H1 2027) and potential partnership or M&A interest given the strength of the data across both on-demand and prophylactic formulations. The ongoing CREAATE study for AAE-C1INH provides additional upside optionality.
Drug in focus
PHVS drug pipeline →deucrictibant
◆ Mixed Named in this 6-K- Impact
- Phase
- Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
- Time to market
- IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
- Next catalyst
- None dated
What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 8 $37.84entry
- T+1 · 2mo ago −0.26%α +0.20% · $37.74
- T+5 · 2mo ago +2.70%α +3.36% · $38.86
- T+20 · 6w ago −17.76%α −19.73% · $31.12
- T+49 · todayOpen
- T+60 · in 15d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris announced overwhelmingly positive topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for prophylaxis of HAE attacks. The study met its primary endpoint with an 83% attack rate reduction versus placebo (p<0.0001) and all secondary endpoints were met with statistical significance, with a well-tolerated safety profile. This data supports planned NDA submissions starting in the first half of 2027, positioning deucrictibant as a potential first-in-class oral therapy with injectable-like efficacy for both on-demand and prophylactic treatment, which is a transformative event for this late-stage biotech company.
Key Facts
- Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in all three types of HAE.
- 87% attack rate reduction versus placebo observed in HAE Type 1 or Type 2 patients.
- All secondary efficacy endpoints met with statistical significance.
- Deucrictibant XR was well tolerated with no treatment-related serious adverse events.
- Marketing authorization applications planned starting in first half of 2027.
- Ongoing regulatory review of NDA for deucrictibant IR for on-demand treatment.
- Topline data from CREAATE study for AAE-C1INH anticipated in Q1 2027.
Financial Impact
Transformative pipeline event for a $2.6B market cap biotech; positive Phase 3 data in a large addressable market (HAE prophylaxis) with potential to capture significant market share from injectable therapies. No financial figures provided in the filing.
Risk Factors
- Regulatory risk: FDA review and potential approval uncertainties remain despite strong data.
- Commercial execution risk: Launching two products (IR and XR) simultaneously requires significant resources.
- Competitive risk: Established injectable therapies (Takhzyro, Haegarda) and emerging oral competitors (Orladeyo) exist in the HAE market.
- Dilution risk: Potential need for additional capital to fund commercial launches and ongoing trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-384339 |
| Document: 6-k_september_8_2026.htm | 0001193125-26-384339 |
| Document: 0001193125-26-384339-index-headers.html | 0001193125-26-384339 |
| Document: 0001193125-26-384339-index.html | 0001193125-26-384339 |
| Document: 0001193125-26-384339.txt | 0001193125-26-384339 |
Track record
51 reports on PHVS
14 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers